Lin Ping

3.0k total citations · 1 hit paper
11 papers, 2.4k citations indexed

About

Lin Ping is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Lin Ping has authored 11 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 3 papers in Surgery and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Lin Ping's work include Diabetes Management and Research (6 papers), Diabetes Treatment and Management (4 papers) and Diabetes and associated disorders (3 papers). Lin Ping is often cited by papers focused on Diabetes Management and Research (6 papers), Diabetes Treatment and Management (4 papers) and Diabetes and associated disorders (3 papers). Lin Ping collaborates with scholars based in United States, Germany and Canada. Lin Ping's co-authors include Matthew C. Riddle, Hertzel C. Gerstein, Scott D. Solomon, Lars Køber, Eldrin F. Lewis, Rafael Díaz, Jeffrey L. Probstfield, Francesca Lawson, John J.V. McMurray and Jean‐Claude Tardif and has published in prestigious journals such as New England Journal of Medicine, Diabetes Care and American Heart Journal.

In The Last Decade

Lin Ping

10 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

2015 1.7k citations Marc A. Pfeffer, Brian Claggett et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lin Ping United States	8	2.2k	919	739	420	332	11	2.4k
Mark Warren United States	14	1.8k 0.8×	745 0.8×	643 0.9×	380 0.9×	192 0.6×	32	2.0k
Thomas Idorn Denmark	19	1.6k 0.7×	498 0.5×	645 0.9×	367 0.9×	281 0.8×	44	2.1k
Ambady Ramachandran India	6	1.5k 0.7×	572 0.6×	448 0.6×	292 0.7×	255 0.8×	9	1.6k
Samuel S. Engel United States	5	1.7k 0.8×	654 0.7×	549 0.7×	246 0.6×	430 1.3×	6	1.9k
Heidrun Bosch‐Traberg Denmark	14	1.2k 0.5×	462 0.5×	425 0.6×	286 0.7×	157 0.5×	25	1.5k
Lisa E. Porter United States	8	1.1k 0.5×	570 0.6×	353 0.5×	277 0.7×	278 0.8×	10	1.5k
Carolina Solis‐Herrera United States	18	1.3k 0.6×	791 0.9×	828 1.1×	158 0.4×	195 0.6×	38	1.7k
Elise Hardy United States	18	1.3k 0.6×	645 0.7×	525 0.7×	323 0.8×	55 0.2×	38	1.4k
R. Camisasca Italy	10	1.0k 0.5×	380 0.4×	369 0.5×	168 0.4×	300 0.9×	13	1.2k
Silvina Gallo United States	10	1.3k 0.6×	596 0.6×	521 0.7×	177 0.4×	277 0.8×	14	1.5k

Countries citing papers authored by Lin Ping

Since Specialization

Citations

This map shows the geographic impact of Lin Ping's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lin Ping with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lin Ping more than expected).

Fields of papers citing papers by Lin Ping

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lin Ping. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lin Ping. The network helps show where Lin Ping may publish in the future.

Co-authorship network of co-authors of Lin Ping

This figure shows the co-authorship network connecting the top 25 collaborators of Lin Ping. A scholar is included among the top collaborators of Lin Ping based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lin Ping. Lin Ping is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Lü, Shuai, Xu‐Liang Nie, Lin Ping, et al.. (2018). Crystal structure of 2-(2-(1-Chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl)-1H-1,2,4-triazole-3(2H)-thione, C₁₄H₁₅Cl₂N₃OS. Zeitschrift für Kristallographie - New Crystal Structures. 233(3). 427–429.

Xie, Lixin, et al.. (2017). The Current Situation of China's Ophthalmology and Visual Science Bioengineering, and a Development Strategy. Strategic Study of CAE. 19(2). 100–100. 1 indexed citations

Derwahl, Karl-Michael, et al.. (2017). Efficacy and Safety of Biosimilar SAR342434 Insulin Lispro in Adults with Type 2 Diabetes, Also Using Insulin Glargine: SORELLA 2 Study. Diabetes Technology & Therapeutics. 20(1). 49–58. 19 indexed citations

Wu, Ming, Jian Su, Xiaoqun Pan, et al.. (2015). Prevalence, awareness, treatment and control of hypertension and sodium intake in Jiangsu Province, China: a baseline study in 2014. BMC Public Health. 16(1). 56–56. 18 indexed citations

Bentley–Lewis, Rhonda, David Aguilar, Matthew C. Riddle, et al.. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 169(5). 631–638.e7. 79 indexed citations

Pfeffer, Marc A., Brian Claggett, Rafael Díaz, et al.. (2015). Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine. 373(23). 2247–2257. 1726 indexed citations breakdown →

Danne, Thomas, R. H. A. Becker, Lin Ping, & Areti Philotheou. (2014). Insulin glargine metabolite 21^A-Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Pediatric Diabetes. 16(4). 299–304. 9 indexed citations

Riddle, Matthew C., Thomas Först, Ronnie Aronson, et al.. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. Diabetes Care. 36(9). 2497–2503. 223 indexed citations

Danne, Thomas, Areti Philotheou, David Goldman, et al.. (2013). A randomized trial comparing the rate of hypoglycemia-assessed using continuous glucose monitoring-in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study). Pediatric Diabetes. 14(8). 593–601. 31 indexed citations

10.

Riddle, Matthew C., Ronnie Aronson, Philip Home, et al.. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care. 36(9). 2489–2496. 247 indexed citations

11.

Ping, Lin. (2005). Preliminary Studies on Anticoagulant Function of Dendrobium chrysanthum. Chinese Journal of Natural Medicines. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact